Myasthenia Gravis

Pharma

Argenx sees early launch success for Vyvgart in CIDP

Vyvgart has reached 300 patients with chronic inflammatory demyelinating polyneuropathy (CIDP) after securing an approval in the disease in late June.

Zoey Becker Nov 1, 2024 11:46am

Amgen's Uplizna posts strong results in myasthenia gravis trial

Sep 25, 2024 11:37am

Argenx's Vyvgart holds its own against AZ's rare disease duo

Jul 25, 2024 3:16pm

Argenx lays out bold ambitions for its chief drug Vyvgart

Jul 18, 2024 10:26am

Argenx gears up to launch Vyvgart in next potential indication

Apr 16, 2024 2:24pm

Roches headquarters in Basel sunset in the background

Enspryng falls short of Roche's expectations in myasthenia gravis

Mar 21, 2024 11:28am